84: MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies

Thanks for your interest in this podcast. Please read this important program information before listening.Episode Description In this podcast, experts Charles C. Wykoff, MD, PhD, FASRS; Jed H. Assam, MD, MS; Diana V. Do, MD; and Dante Pieramici, MD, FASRS; discuss the diagnosis, clinical features, and evolving management strategies for patients diagnosed with macular telangiectasia (MacTel) type 2.Learning Objectives Upon successful completion of this activity, you should be better prepared to: Summarize the limitations of anti-VEGF intravitreal injection therapies in the management of MacTel. Evaluate emerging evidence supporting the use of novel therapies in the management of MacTel. Integrate current evidence-based interventions for MacTel into clinical practice to optimize disease outcomes. Apply advanced diagnostic and therapeutic interventions to the management of MacTel. Acknowledgment of Educational Grant SupportThis activity is supported by an educational grant from Neurotech Pharmaceuticals, Inc.Faculty:Charles C. Wykoff, MD, PhD, FASRSDirector of Research, Retina Consultants of TexasChairman of Research & Clinical Trials, Retina Consultants of AmericaHouston, TXDisclosures: Consultant/Honoraria: 4DMT, AbbVie, Acuta, ADARx, Adverum, Alcon, Alimera, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis, Arrowhead, Ascidian, Astellas, Aviceda, Bausch + Lomb, Bayer, BioCryst, Bionic Vision, Boehringer Ingelheim, Chengdu Kanghong, Curacle, Emmecell, Eyebiotech, EyePoint, Genentech, InGel, Janssen, Kiora, Kodiak, Kowa, Nanoscope, Neurotech, NGM, Novartis, Oak Bay Bio, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Opus, Osanni, Oxular, Palatin, Perceive Bio, Perfuse, Ray, Regeneron, Regenxbio, RetinAI, Roche, Samsung Bioepis, Sandoz, Sanofi, Santen, Skyline, Stealth, Sylentis, TCG Crossover, THEA, Therini, VH401,Visgenx, Zeiss; Research Grants: 4DMT, AbbVie, Adverum, AffaMed, Alexion, Alimera, Allgenesis, Amgen, Annexin, Annexon, Apellis, Ascidian, AsclepiX, Astellas, Aviceda, Avirmax, Bayer, Boehringer Ingelheim, Chengdu Origen, Clearside, Curacle, Eluminex, Eyebiotech, EyePoint, Genentech, IONIS, iRenix, Janssen, Kalaris, Kodiak, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Ollin, Opthea, Outlook Therapeutics, Oxular, Oxurion, Perceive Bio, Pykus, Regeneron, Regenxbio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline, VH401; Stock Options (Not Owner) From Private For-Profit Entities: InGel, Ollin, ONL, Osanni, Panther, TissueGen, Visgenx, VitranuDiana V. Do, MDVice Chair of Clinical AffairsProfessor of OphthalmologyThe Byers Eye InstituteStanford University School of MedicinePalo Alto, CADisclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Apellis, Astellas, Belite Bio, LumiThera, Oculis, Regenxbio; Grant/Research Funding: Apellis, Belite Bio, LumiThera, Neurotech, Oculis, Regeneron, Regenxbio; Ownership Interests in Publicly-Traded Companies: Belite Bio, Kodiak SciencesDante Pieramici, MD, FASRSMedical Director, Clinical Research, California Retina ConsultantsDirector, California Retina Research FoundationPartner, California Retina Consultants/Retina Consultants of AmericaSanta Barbara, CA Disclosures: Advisory: Perceive; Consultant: 4DMT, Adverum, Eyepoint, Genentech, Neurotech, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Roche, Samsung, Unity; Research Funding: 4DMT, Adverum, Eyepoint, Genentech, Novartis, Ocular, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Roche; UnityJed H. Assam, MDClinical FacultyDepartment of SurgeryUniversity of South DakotaSanford School of MedicineSioux Falls, SDDisclosures: Jed H. Assam, MD, has no relevant financial relationships with ineligible companies. Faculty, Staff, and Planners’ DisclosuresIn accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.To learn more about this topic, including the diagnosis and interdisciplinary management of MacTel, go to https://www.gotoper.com/courses/mactel-decoded-rethinking-conventional-approaches-with-novel-neuroprotective-strategies.Release DateJanuary 30, 2026Expiration DateJanuary 30, 2027Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.